NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDAbatacept Orencia® Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
SCGMethotrexate
(For rheumatology - SCG) 		Musculoskeletal and joint diseases, Drugs affecting the immune response, 10.01.03
REDSarilumab 150mg, 200mg
(Pre-filled pen or syringe) 		Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
SCGSulfasalazine  Musculoskeletal and joint diseases, Sulfasalazine, 10.01.03
REDTetracosactide 1mg Synacthen Depot ®
(Injection) 		Endocrine system, Hypothalamic and anterior pituitary hormones and anti-oestrogens, 06.05.01
REDUstekinumab 45mg, 90mg Pyzchiva® Wezenla®
(Pre-filled syringe) 		Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
Non Formulary items found
Status Description Section
 Capsaicin 0.025% Zacin®
(Cream) 		Musculoskeletal and joint diseases, Capsaicin, 10.03.02
DNPHyaluronic acid  Musculoskeletal and joint diseases, Osteoarthritis and soft-tissue disorders, 10.01
DNPHylan G-F 20 Synvisc® Musculoskeletal and joint diseases, Osteoarthritis and soft-tissue disorders, 10.01
DNPSodium hyaluronate and triamcinolone hexacetonide Cingal Musculoskeletal and joint diseases, Osteoarthritis and soft-tissue disorders, 10.01
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Abatacept Abatacept Musculoskeletal System, Immunosuppressants, T-Cell Activation Inhibitors
Arthritis
Aceclofenac Aceclofenac Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Adalimumab Adalimumab Musculoskeletal System, Immunosuppressants, Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Arthritis
Anakinra Anakinra Musculoskeletal System, Immunosuppressants, Interleukin Inhibitors
Arthritis
Apremilast Apremilast Musculoskeletal System, Phosphodiesterase Type-4 Inhibitors
Arthritis
Azathioprine Azathioprine Musculoskeletal System, Immunosuppressants, Antimetabolites
Arthritis
Baricitinib Baricitinib Musculoskeletal System, Immunosuppressants, JAK Inhibitors
Arthritis
Bimekizumab Bimekizumab Musculoskeletal System, Immunosuppressants, Interleukin Inhibitors
Arthritis
Capsaicin Capsaicin Musculoskeletal System, Analgesics, Plant Alkaloids
Arthritis
Celecoxib Celecoxib Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Certolizumab  Certolizumab Pegol Musculoskeletal System, Immunosuppressants, Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Arthritis
Chloroquine  Chloroquine Musculoskeletal System, Antiprotozoals, Antimalarials
Arthritis
Ciclosporin Ciclosporin Musculoskeletal System, Immunosuppressants, Calcineurin Inhibitors And Related Drugs
Arthritis
Cyclophosphamide Cyclophosphamide Musculoskeletal System, Antineoplastic Drugs, Alkylating Agents
Arthritis
Diclofenac Diclofenac Potassium Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Diclofenac Diclofenac Sodium Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Etanercept Etanercept Musculoskeletal System, Immunosuppressants, Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Arthritis
Etodolac Etodolac Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Etoricoxib  Etoricoxib Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Filgotinib Filgotinib Musculoskeletal System, Immunosuppressants, JAK Inhibitors
Arthritis
Flurbiprofen Flurbiprofen Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Glucosamine Glucosamine Musculoskeletal System, Chondroprotective Drugs
Arthritis
Golimumab Golimumab Musculoskeletal System, Immunosuppressants, Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Arthritis
Guselkumab Guselkumab Musculoskeletal System, Immunosuppressants, Interleukin Inhibitors
Arthritis
Hydroxychloroquine Hydroxychloroquine Sulfate Musculoskeletal System, Disease-Modifying Anti-Rheumatic Drugs
Arthritis
Ibuprofen Ibuprofen Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Indometacin Indometacin Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Infliximab Infliximab Musculoskeletal System, Immunosuppressants, Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Arthritis
Ixekizumab Ixekizumab Musculoskeletal System, Immunosuppressants, Interleukin Inhibitors
Arthritis
Ketoprofen Ketoprofen Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Leflunomide Leflunomide Musculoskeletal System, Disease-Modifying Anti-Rheumatic Drugs
Arthritis
Mefenamic  Mefenamic Acid Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Meloxicam Meloxicam Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Methotrexate Methotrexate Musculoskeletal System, Antineoplastic Drugs, Antimetabolites
Arthritis
Nabumetone Nabumetone Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Naproxen Naproxen Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Penicillamine Penicillamine Musculoskeletal System, Antidotes And Chelators, Copper Chelators
Arthritis
Penicillamine Penicillamine Musculoskeletal System, Disease-Modifying Anti-Rheumatic Drugs
Arthritis
Piroxicam Piroxicam Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Risankizumab Risankizumab Musculoskeletal System, Immunosuppressants, Interleukin Inhibitors
Arthritis
Rituximab  Rituximab Musculoskeletal System, Antineoplastic Drugs, Monoclonal Antibodies
Arthritis
Sarilumab  Sarilumab Musculoskeletal System, Immunosuppressants, Interleukin Inhibitors
Arthritis
Secukinumab  Secukinumab Musculoskeletal System, Immunosuppressants, Interleukin Inhibitors
Arthritis
Sulfasalazine Sulfasalazine Musculoskeletal System, Aminosalicylates
Arthritis
Sulindac Sulindac Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Tenoxicam Tenoxicam Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Tiaprofenic  Tiaprofenic Acid Musculoskeletal System, Analgesics, Non-Steroidal Anti-Inflammatory Drugs
Arthritis
Tocilizumab Tocilizumab Musculoskeletal System, Immunosuppressants, Interleukin Inhibitors
Arthritis
Tofacitinib Tofacitinib Musculoskeletal System, Immunosuppressants, JAK Inhibitors
Arthritis
Upadacitinib Upadacitinib Musculoskeletal System, Immunosuppressants, JAK Inhibitors
Arthritis
Ustekinumab  Ustekinumab Musculoskeletal System, Immunosuppressants, Interleukin Inhibitors
Arthritis
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
BLMK APC Biologics Treatment pathway for Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (nrAxial SpA)
BLMK APC Treatment Pathway for Active Psoriatic Arthritis (non-Axial PsA) after inadequate response to DMARDs
BLMK APC Treatment pathway for Moderate Rheumatoid Arthritis
BLMK APC Treatment Pathway for Severe Rheumatoid Arthritis
JPC Biologics Treatment Pathway for ankylosing spondylitis and Non-radiographic Axial Spondyloarthritis (March 2018)
MHRA DSU 2016: Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis
NICE TA 433: Apremilast for treating active psoriatic arthritis
NICE TA 715 Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
NICE TA 719 Secukinumab for treating non-radiographic axial spondyloarthritis, Technology appraisal guidance
NICE TA1104: Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (TERMINATED APPRAISAL)
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199)
NICE TA220: Psoriatic arthritis - golimumab
NICE TA225: Rheumatoid arthritis - golimumab
NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
NICE TA247: Rheumatoid arthritis - tocilizumab (rapid review TA198)
NICE TA340 - treating active psoriatic arthritis
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375:Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
NICE TA485:Sarilumab for moderate to severe rheumatoid arthritis
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
NICE TA711: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA735 Tofacitinib for treating juvenile idiopathic arthritis
NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis
NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA803 Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis
NICE TA916: Bimekizumab for treating active psoriatic arthritis
NICE TA918: Bimekizumab for treating axial spondyloarthritis
NICE TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (TERMINATED APPRAISAL)
TA676 Filgotinib for treating moderate to severe rheumatoid arthritis